subtypes combined (OR 1.18; 95% CI 1.10-1.28 per year increase in age). The association was observed in men and women, and in all categories of final adult height. Conclusions We observed for the first time a positive association between glioma risk and a prolonged adolescent growth phase. Our results suggest a role for factors governing the timing and intensity of growth in adolescence as risk-determining exposures in adult glioma.
fifth decade of life, is higher in males, and is elevated in Caucasians when compared to other racial groups in the US [1] . The risk of glioma is higher in some rare inherited syndromes [2] , and genetic susceptibility has been documented with the identification of single-nucleotide variants associated with increased or decreased risk of glioma in genome-wide association studies [3] . Of the many environmental exposures studied, only ionizing radiation is a confirmed cause of primary human brain tumors [4] . However, the immune system response to the environment may also impact glioma in that a history of chicken pox [5] and respiratory allergies [6] are protective against glioma.
Taller stature is associated with an increased risk of several malignancies [7] , although an association in glioma remains equivocal [8] [9] [10] [11] [12] . Posited mechanisms relating greater height to cancer risk include metabolic and molecular interactions during human development [13, 14] . We and others have reported that glioma risk varies with other developmental milestones including increased risk with an elevated body mass index (BMI) in early adulthood, but not later in life [9, 11] , and with an increased age at menarche in women [15, 16] . These findings taken together suggest that growth and maturation during adolescence may be important factors in adult glioma risk.
To shed further light on this hypothesis, we examined the association of age when height is attained with the risk of glioma in the context of a large US-based case-control study geographically confined to the southeastern United States. To the best of our knowledge, ours is the first study to consider the association of the timing of attainment of adult height during the lifespan with onset of glioma.
Materials and methods

Study population
Subjects in the analysis were enrolled in a clinic-based case-control study examining risk factors for adult glioma. All individuals were aged 18 or older. Glioma cases had a recent (within 3 months) primary diagnosis of glioma and were identified in neurosurgery and neuro-oncology clinics in the Southeastern US including Vanderbilt University Medical Center (Nashville, TN), Moffitt Cancer Center (Tampa, FL) and affiliated hospitals, University of Alabama at Birmingham (Birmingham, AL), Emory University (Atlanta, GA), and Norton Cancer Institute (Louisville, KY). Eighty-seven percent of eligible glioma patients were enrolled in the study and completed the study interview with a median of 1.0 month following the glioma diagnosis (interquartile range 2 weeks-1.7 months). Controls were friends or non-blood-related family members (n = 80) of cases or were identified through telephone listings with frequency matching to cases on age, gender, race, and neighborhood via postal zip code (n = 871). An estimated 50% of contacted eligible households yielded a participating control. Enrollment was conducted between December 2004 and July 2014. Institutional Review Boards of each participating institution approved the study. Written informed consent was obtained from all participants.
Data collection
Demographic data and information on known and suspected glioma risk factors were collected in structured interviews [11, 17] . For purposes of the current study, participants were asked to report the age at which they reached their maximum height. Portions of the questionnaire were previously validated [11] based on a second interview of 148 control subjects interviewed 2-4 months following the initial interview, which yielded strong correlation between first and second responses for adult height (Spearman r = 0.99). (Age at height attainment was not included in the second interview).
Statistical analysis
Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) associated with the exposure of age at attainment of maximum adult height. After excluding individuals who did not report age when height was attained, the analysis included 951 controls and 776 glioma cases. Demographic covariates included in all multivariate models were age at interview, race (Caucasian, non-Caucasian), sex, level of education (high school or less, some college, college degree, graduate degree), and US state of residence (AL, FL, GA, KY, TN, other). Previously, height [8, 9, 12] and age at menarche [15] were found to be associated with glioma risk. Therefore, also included in multivariate models were final adult stature (continuous) and, in models restricted to women, age at menarche (<10, 10-12, 13-14, >14 years). We examined associations of age at height attainment with glioma risk, overall, and according to glioma grade (glioblastoma and non-glioblastoma) and gender, for five levels of age at height attainment (≤15 years [referent], 16, 17, 18, and ≥19). We also considered associations according to tertile of final adult height (short, average, tall) with tertile cut-points established separately in males and females based on sex-specific distributions of reported height at age 21; four levels of exposure (≤16 years [referent group], 17, 18, and ≥19) were considered given the sparse data per cell.
Spearman's rank correlations were calculated to test for potential relationships between adult height, age at maximum height, and age at menarche.
Statistical analyses were performed using SAS Version 9.4 (SAS Institute, Inc., Cary, NC). A p-value <0.05 was considered statistically significant, and all statistical tests were two-sided.
Results
Demographics
Descriptive characteristics of study participants are summarized in Table 1 . Median age for cases and controls were 56 and 57 years old, respectively. Men comprised over half of cases (57.0%) and controls (51.2%), and the majority of participants were Caucasian. Controls were more likely than cases to be college graduates (28.5% vs. 22.4%). Overall, controls were well matched to cases by age, gender, and race. Glioblastoma was the largest subgroup of gliomas (n = 501; 64.6%).
Self-reported mean adult height was 64.9 inches (SD = 2.6) for women and 70.7 inches (SD = 2.8) for men. The median age when maximum height was reached was 16 years in women (interdecile range 13-19 years) and 18 years in men (interdecile range 15-20 years) (results not shown).
Age at height attainment and risk of glioma
Increasing age at height attainment was significantly associated with an overall increased risk of glioma ( 
Correlations between developmental milestones and adult height
Among 798 women in the analysis, 768 (96.2%) women reported age at menarche. Three percent of women reported their first menstrual cycle before the age of 10, 45.4% ages 10-12, 38.8% ages 13-14, and 12.8% were over the age of 14 years. Women's final height and age at menarche were not highly correlated (Spearman r = 0.07; p = 0.01), whereas age at height attainment was positively correlated with age at menarche (Spearman r = 0.20; p < 0.0001), consistent with declining rate and cessation of growth around the time of puberty [18] . Age when maximum height was achieved and final height were uncorrelated in women (Spearman r = −0.01; p = 0.68) and men (Spearman r = −0.1; p = 0.78).
Associations according to gender
A positive association with increased age at final height and glioma risk was observed in men (multivariate OR 1.15, 95% CI 1.07-1.24, per year increase in age) and in women (multivariate OR 1.11, 95% CI 1.03-1.19, per year increase in age) ( Table 3 ). The inclusion of adult height and age at 
Associations according to final adult height
A significant positive association of glioma with age at height attainment was observed regardless of final adult height ( 
Discussion
In this study of 951 controls and 776 glioma cases, older age at height attainment was associated with an increased risk of glioma. The association was observed in men and women, and found for both glioblastoma and non-glioblastoma tumors. Moreover, when data were stratified according to final height, a positive association with older age at final height was observed regardless of the final height attained. To our knowledge, this is the first study to examine the timing of height attainment in relation to adult glioma risk, with results suggesting that adolescent growth and development may contribute to the risk of glioma onset in later life. In line with these results, previous studies support a link between growth in early life and glioma risk. In the Swedish Birth Registry cohort, Crump et al. [19] reported that high fetal growth (determined by standardized intrauterine growth curves) was associated with an increased risk of glioma in childhood and early adulthood. Suggestive results were also noted for a higher birth weight and length, although tests for trend did not reach significance [19] . Using the Copenhagen School Health Records Register (CSHRR), Kitahara and colleagues [20] found that individuals who were larger babies and men who were taller boys between the ages of 7 and 13 had a higher risk of adult glioma [20] . Risk associations with growth in early life have also been observed in other cancers. The aforementioned CSHRR cohort demonstrated positive associations between height in childhood with the risk of prostate [21] and thyroid cancers [22] . Similar associations have been observed in breast, colorectal, hematopoietic, and endometrium cancers [23] . The current results thus add further evidence linking early-life body size and growth velocity with the risk of adult cancer across a spectrum of tumors including glioma. The relationship of glioma risk with age at height attainment in the present study was observed regardless of glioma grade, although data were consistent with a more prominent association in lower grade gliomas. Lower grade tumors develop in younger persons than do glioblastomas and tend to have a more indolent course [24] . We are unaware of any mechanism to explain the observed stronger association in non-glioblastomas, and these findings may be due to chance.
The present findings suggest the timing of, or prolonged exposure to growth factors such as growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in childhood may contribute to adult glioma risk. Normal linear growth during adolescence is dependent on GH and IGF-1. GH stimulates growth plates in the vertebrae and long bones, notably in the leg, in addition to regulating the production and circulation of IGF-1 [25] , which possesses strong anti-apoptotic properties [14] . The ability of IGF-1 to prevent programed cell death and increase the rate of mitosis is crucial during development, but is also hallmark characteristics of cancer [14] . Some studies link longer leg length attributing to total stature to greater risk of cancer [14] . Serum levels of IGF-I have been linked to cancer risk [26] and are positively associated with growth rate in children [27] . The present results could indicate that elevated or prolonged exposure to IGF-I or other growth factors during the adolescent growth phase may contribute to glioma risk in later life.
Linear growth ends around the time of menarche [18] , and we [15] and others [16] have reported that delayed menarche is associated with an increased risk of glioma in women. However, all associations persisted after multivariate adjustment for age at menarche in women, and final height, so that present findings are unlikely to reflect confounding by these factors. Puberty also marks the beginning of cyclic estrogen exposure in women, and a later menarche is associated with reduced lifetime exposure to estrogen (accounting for the negative association between age at menarche and breast cancer risk [28] ). Estrogen could be protective for glioma, as observed for several neurodegenerative diseases as well as brain injury [29] , and may explain the lower incidence of glioma in women [30] . In support of this hypothesis, some studies indicated a protective association of exogenous estrogens (e.g., hormone replacement after menopause) with glioma risk [16] . However, a mechanism related to estrogen for the current findings (via cessation of growth with an earlier puberty) would not explain findings observed also in men. Finally, the present results could indicate relationships with prenatal and childhood nutrition as calorie restriction and lower socioeconomic status have been linked to slower development in childhood and shorter adult stature [31] [32] [33] . Although only speculation, the present observations support the possibility that early-life nutrition drives growth velocity and also the timing of puberty, and, in turn exposure to hormones and growth factors that influence organ size and glial tissue at risk for tumor development decades later.
Strengths and limitations
Strengths of this study include its large size in a histologically-confirmed rare disease. Furthermore, a large majority of eligible glioma cases were enrolled in the study. Lower than optimal response rates in controls is a limitation, although we can posit no reason that selective enrollment of controls on the primary exposure could explain reported associations with age at attained height. Furthermore, findings were robust, with similar associations demonstrated in all examined subgroups of participants. As with any case-control study, the reliance on lucid memories of participants presents a possible limitation. Middle-aged individuals were able to recall their adolescent height relative to their peers [34] , and elderly men and women were able to reasonably recall their height in the last year of high school [35] offering assurance that age at height attainment was recalled with reasonable accuracy. Furthermore, the age when one completes growth surrounds memorable life events to aid in recall, such as procuring a driver's license and matriculation, and timing of menarche in women [34] . Given height, age at adult height, and age at menarche are not publicized risk factors of glioma, we would expect reporting error to be random and results, if anything, biased toward the null.
Summary
To our knowledge, this is the first report linking age of actualization of maximum height with subsequent risk of glioma. We observed a positive association between a prolonged adolescent growth phase and glioma risk, regardless of sex, glioma grade, and final stature. A postulated mechanism is that a prolonged growth phase may increase exposure to as-yet unknown growth factors that enhance glioma risk. These findings suggesting complex interactions with the timing and intensity of risk-promoting exposures in glioma warrant further study.
